British Patient Capital

OMass Therapeutics is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics against challenging disease targets.

Oxford Quantum Circuits developing technology using the power of quantum to do things that have never been achieved before, from enabling life-changing drug discoveries to developing new battery technologies. OQC's quantum computer is a fully functional unit that includes the control system, hardware, and software. Customers can use OQC's quantum computers to streamline their businesses, pioneer new approaches, and help solve some of humanity's most pressing issues, such as slowing climate change and feeding a rapidly growing population.

CloudNC develops advanced software that enables factories to autonomously manufacture precision parts. Precision manufacturing is fundamental to every aspect of modern life - without it, there are no cars, aircraft, or ships. No mobile phones or computers. No houses or hospitals, no factories or power plants. No food. In the modern world, virtually nothing can be made without precision parts. And yet, the manufacturing industry has been slow to modernize and adopt the innovations that are shaping the future. CloudNC's mission is to automate manufacturing and create a clean and sustainable industrial revolution that accelerates humanity. They’re building the autonomous factories of the future to make manufacturing 10x more efficient, sustainable and faster than anything today. They’re reimagining manufacturing, making it more efficient and productive than ever before, and opening a unique opportunity for investors to transform a $150bn industry. CloudNC elevates an entire industry and put manufacturing back at the cutting edge.

Proximie is a health technology platform that enables surgeons to virtually attend operating theaters to visually guide complex surgeries. Proximie combines human expertise with the power of augmented reality, artificial intelligence, and machine learning to allow a surgeon to remotely watch an operation and use their hands to demonstrate things to the surgeon conducting the operation, who sees the remote surgeon on a screen. This platform aims to democratize access to the most up-to-date and skilled knowledge on surgery practice, by helping surgeons advise each other from different parts of the world. The company was founded by Nadine Hachach-Haram in 2016 and is headquartered in London, England.

IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor.

Microbiotica is a developer of human microbiome therapeutics intended to discover and develop live bacterial therapeutics and biomarkers. The company's therapeutics identify gut bacteria linked to phenotype with unprecedented precision, enabling researchers to phenotype before testing of candidate bacteria in advanced human in vitro and in vivo models.

Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions. Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.

Thought Machine is a Fintech company that builds cloud-native technology to revolutionize core banking. Its mission is to cure one of the banking industry's primary problems: its reliance on outdated IT infrastructure. Nearly every bank is stuck on a legacy IT platform, which cripples their ability to innovate and give their customers the type of service they deserve. The company provides a solution to this is Vault: a complete retail banking platform that is capable of being configured easily to suit the needs of any bank. They have built Vault from the ground up as a cloud-native, microservice API architecture platform. Thought Machine has a deep culture of engineering excellence, and they believe it is this which delivers a solution compelling enough to engender a seismic shift in the banking industry.

Accurx is where conversations happen with and about patients. Through one, easy-to-use platform, we help everyone involved in a patient’s care to communicate and collaborate. Whether you’re a patient or a healthcare professional, Accurx lets you connect seamlessly with the people you need to. You can use Accurx to: send SMS messages and medical surveys, provide appointment reminders and referrals, hold video consultations, and manage virtual wards, outpatient clinics and follow-up pathways. Accurx is used by 98% of GP practices and in 50% of NHS trusts.

Quantexa is a global data and analytics software company pioneering Contextual Decision Intelligence that empowers organizations to make trusted operational decisions by making data meaningful. The platform helps organizations protect, optimize, and grow by leveraging AI to unify siloed data, identify opportunities, and mitigate fraud. Using the latest advancements in big data and AI, Quantexa's platform uncovers hidden risks and new opportunities by providing a contextual, connected view of internal and external data in a single place.

Thought Machine is a Fintech company that builds cloud-native technology to revolutionize core banking. Its mission is to cure one of the banking industry's primary problems: its reliance on outdated IT infrastructure. Nearly every bank is stuck on a legacy IT platform, which cripples their ability to innovate and give their customers the type of service they deserve. The company provides a solution to this is Vault: a complete retail banking platform that is capable of being configured easily to suit the needs of any bank. They have built Vault from the ground up as a cloud-native, microservice API architecture platform. Thought Machine has a deep culture of engineering excellence, and they believe it is this which delivers a solution compelling enough to engender a seismic shift in the banking industry.

Quantexa is a global data and analytics software company pioneering Contextual Decision Intelligence that empowers organizations to make trusted operational decisions by making data meaningful. The platform helps organizations protect, optimize, and grow by leveraging AI to unify siloed data, identify opportunities, and mitigate fraud. Using the latest advancements in big data and AI, Quantexa's platform uncovers hidden risks and new opportunities by providing a contextual, connected view of internal and external data in a single place.